Prime Medicine’s (PRME) treatment of retinal dystrophy due to USH2A gene mutations was granted FDA orphan designation, according to a post to the agency’s website.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRME:
- Prime Medicine Advances Gene Editing for Liver Diseases
- Prime Medicine presents data from multiple studies showcasing LNP platform
- Prime Medicine granted orphan status for glycogen storage disease
- Stellantis cuts 2024 targets, TPG acquires AT&T’s DirecTV stake: Morning Buzz
- Prime Medicine prioritization, Bristol deal positive, says Morgan Stanley